Use of Lumella-glycosylated Fibronectin for Diagnosis of Preeclampsia (Lumella)
Lumella is a Point of Care Blood Test Used Together With Other Blood Tests to Assess the Risk of Preeclampsia in Pregnancy in 10 Minutes. Measurements of the Biomarker.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pre-eclampsia is a potentially serious condition that affects pregnant women. It is usually diagnosed during routine antenatal appointments. This is based on blood pressure measurements and results of urine protein tests that are recommended at each routine antenatal visit to screen for the condition. The Triage PlGF test and the Elecsys immunoassay sFlt-1/PlGF ratio is also recommended to help rule out the condition in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks of pregnancy plus 6 days. If diagnosed with pre-eclampsia, women are usually referred to a specialist in hospital for further tests and more frequent monitoring. Depending on the severity of the condition, some women may be monitored as outpatients while others may need admission to hospital for closer monitoring or to have the condition managed in a critical care setting.
The Lumella test is based on the novel biomarker GlyFn. The company states that compared with other currently used biomarkers (such as soluble fms-like tyrosine kinase-1 [sfIT-1] and placental growth factor [PlGF] or PlGF alone), GlyFn is etiological to pre-eclampsia and maintains a linear progression throughout pregnancy. The company also claims that the test offers improved sensitivity and specificity over standard care tests. This would lead to a reduction in false positives and false negatives. The Lumella test requires a finger prick blood sample (5 microlitres). Other pre-eclampsia tests currently used in the NHS need a phlebotomy blood sample, which can be difficult to collect in some people. The test can also be transported and stored at room temperature. Other tests for pre-eclampsia need to be refrigerated and brought to room temperature before the test can be done. The Lumella test may improve patient experience and allow a more rapid turnaround time for results. The company states that Lumella is currently the only test that can be done within 10 minutes at room temperature.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: michael chang
- Phone Number: +442084013610
- Email: michael.chang@nhs.net
Study Contact Backup
- Name: Daniel Annan
- Phone Number: 5283 +442084013000
- Email: daniel.annan@nhs.net
Study Locations
-
-
Surrey
-
Croydon, Surrey, United Kingdom, CR7 7YE
- Croydon University Hospital
-
Contact:
- michael chang
- Phone Number: +442084013610
- Email: michael.chang@nhs.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- If they can speak English
- Can give informed consent
- Has symptoms of Preeclampsia
Exclusion Criteria:
- Can't speak English
- Does not want to participate
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Women with preeclampsia
women with symptoms of preeclampsia from antenatal clinic or triage will be offered Lumella test along with traditional blood tests.
If Lumella test is positive which will be compared with the traditional blood test results.
Once 50 positive cases have been analysed the study results will be submitted to NICE.
|
Finger prick blood test
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
can we use a bedside test -glycosylated fibronectin for the early diagnosis of pre-eclampsia
Time Frame: 6 months
|
Does the test work?
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Is glycosylated fibronectin better than placental growth factor or traditional blood tests
Time Frame: 6 months
|
Is the test better than PLGF/traditional blood tests
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bini Ajay, Croydon University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 329116
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.